WHAT IS ALS?

Amyotrophic Lateral Sclerosis (ALS) is one of the most severe and debilitating disorders of the nervous system. In The Netherlands, we currently number around 1,500 patients; 500 patients are added each year, but 500 patients also die yearly.

‘’After the first symptoms the average
life expectancy is 3 to 5 years’’.

What is ALS?

Amyotrophic Lateral Sclerosis (ALS) is one of the most severe and debilitating disorders of the nervous system. In The Netherlands, we currently number around 1,500 patients; 500 patients are added each year, but 500 patients also die yearly.

‘’After the first symptoms the average life expectancy
is 3 to 5 years ’’.

Victus Sports believes it is important that we contribute to a better society and that every individual should be able to live a healthy life. Victus/Sports wants to contribute actively by donating part of its turnover to Stichting ALS every month. In this way, together with you, we want to actively contribute to a permanent solution to the disease ALS, by stimulating and sponsoring scientific research on this deadly disease

Although research into the disease is being conducted worldwide, the cause is unknown to date. Hope for a future – with an average life expectancy of 3 to 5 years after the first symptoms – is not yet available for these 1500 patients.

The relatively small number of patients makes research budgets of the pharmaceutical industry and the government nil; the vast majority of scientific research into ALS is funded by donations to the ALS Foundation. This makes it essential that companies such as Victus/Sports take the initiative to fund research.

Victus Sports believes it is important that we contribute to a better society and that every individual should be able to live a healthy life. Victus/Sports wants to contribute actively by donating part of its turnover to Stichting ALS every month. In this way, together with you, we want to actively contribute to a permanent solution to the disease ALS, by stimulating and sponsoring scientific research on this deadly disease.

Although research into the disease is being conducted worldwide, the cause is unknown to date. Hope for a future – with an average life expectancy of 3 to 5 years after the first symptoms – is not yet available for these 1500 patients.

The relatively small number of patients makes research budgets of the pharmaceutical industry and the government nil; the vast majority of scientific research into ALS in the Netherlands is funded by donations to Stichting ALS Nederland. This makes it essential that companies such as Victus/Sports take the initiative to fund research.